Role of rasagiline in treating Parkinson’s disease: Effect on disease progression

Rasagiline is a second generation, selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It has demonstrated efficacy in monotherapy for early Parkinson’s disease (PD) patients in one large randomized, placebo-controlled trial (TVP-1012 in Early Monotherapy for Parkinson’s Disease Outp...

Descripción completa

Detalles Bibliográficos
Autores principales: Malaty, Irene A, Fernandez, Hubert H
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695242/
https://www.ncbi.nlm.nih.gov/pubmed/19753135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695242/
https://www.ncbi.nlm.nih.gov/pubmed/19753135

Ejemplares similares